Engineered Probiotics Show Promise in Fighting Pancreatic Cancer in Animal Studies

Scientists have developed a novel approach to treating pancreatic cancer by engineering probiotic bacteria to act as tiny drug factories. In laboratory studies, these modified microbes were able to penetrate pancreatic tumors in animals, triggering immune responses that slowed tumor growth.

The research, conducted by a team of biologists and oncologists, involved altering common probiotic strains to deliver therapeutic molecules directly to cancer cells. The bacteria were designed to survive in the harsh environment of pancreatic tumors, where traditional drugs often struggle to reach their targets.

When combined with standard treatments like chemotherapy, radiation, or immunotherapy, the engineered probiotics showed enhanced effectiveness in reducing tumor size. This synergy suggests the potential for a multi-pronged strategy that could improve outcomes for patients with this aggressive cancer.

While the findings are preliminary and based on animal models, researchers emphasize the importance of further studies to test the approach in humans. The work highlights a new frontier in cancer treatment that leverages the body’s natural microbiome to combat disease.

Based on reporting from ScienceDaily (Cancer).

Source: ScienceDaily (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.